Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Inclusion Criteria: * Histologically confirmed persistent or recurrent ovarian epithelial or primary peritoneal carcinoma * Measurable disease * At least 20 mm by conventional techniques (e.g., palpation, x-ray, plain CT scan, or MRI) OR at least 10 mm by spiral CT scan * Must have had prior therapy with no more than 1 platinum-based chemotherapy regimen for primary disease (e.g., carboplatin, cisplatin, or other organoplatinum compound) * A second regimen containing paclitaxel allowed provided patient received no prior paclitaxel therapy * Platinum-sensitive disease * Treatment-free interval without progressive disease for more than 6 months but less than 12 months after therapy with platinum-based regimen * At least 1 target lesion outside previously irradiated field * Ineligible for higher priority GOG protocol * Performance status - GOG 0-2 (if received 1 prior therapy regimen) * Performance status - GOG 0-1 (if received 2 prior therapy regimens) * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT no greater than 2.5 times ULN * Alkaline phosphatase no greater than 2.5 times ULN * Creatinine no greater than 1.5 times ULN * No evidence of acute ischemia or significant conduction abnormality (e.g., left anterior hemiblock in the presence of right bundle branch block or second or third degree atrioventricular block) on electrocardiogram * No myocardial infarction within the past 6 months * No cerebrovascular event or transient ischemic attack within the past 6 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active infection requiring antibiotics * No other invasive malignancy within the past 5 years except non-melanoma skin cancer * No sensory or motor neuropathy greater than grade 1 * No more than 1 prior non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule inhibitors of signal transduction) for recurrent or persistent disease * At least 4 weeks since prior biological or immunological agents and recovered * No prior cytotoxic chemotherapy for recurrent or persistent disease, including retreatment with initial chemotherapy regimen * At least 4 weeks since prior chemotherapy and recovered * At least 1 week since prior anti-cancer hormonal therapy and recovered * Concurrent hormone replacement therapy allowed * At least 4 weeks since prior radiotherapy and recovered * No prior radiotherapy to target lesions * No prior radiotherapy to more than 25% of marrow-bearing areas * At least 4 weeks since prior surgery and recovered * No prior bortezomib * No prior anti-cancer therapy that would preclude study treatment * No concurrent amifostine or other protective agents